Showing results (11-20 of 16) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Medicinal Chemistry|April 20, 2013
Rational design and binding mode duality of MDM2-p53 inhibitorsFelix Gonzalez-Lopez de Turiso, Daqing Sun, Yosup Rew, et al.Journal of Medicinal Chemistry|July 15, 2016
Discovery and in Vivo Evaluation of the Potent and Selective PI3Kδ Inhibitors 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-5-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-1430)Felix Gonzalez-Lopez de Turiso, Xiaolin Hao, Youngsook Shin, et al.Journal of Medicinal Chemistry|April 25, 2012
Structure-based design of novel inhibitors of the MDM2-p53 interactionYosup Rew, Daqing Sun, Felix Gonzalez-Lopez De Turiso, et al.Journal of Medicinal Chemistry|December 4, 2014
Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune diseaseTimothy D Cushing, Xiaolin Hao, Youngsook Shin, et al.Journal of Medicinal Chemistry|May 7, 2024
Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple SclerosisMartin K Himmelbauer, Bekim Bajrami, Rebecca Basile, et al.Journal of Medicinal Chemistry|January 25, 2014
Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical developmentDaqing Sun, Zhihong Li, Yosup Rew, et al.Pageof 2